NCT07069595 - PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2028

Conditions

Breast CancerResidual DiseaseTriple Negative Breast Cancer (TNBC)Stage II/III

Interventions

DRUG

Datopotamab deruxtecan

Dato-DXd is administered adjuvantly at 6 mg/kg IV for eight cycles.

DIAGNOSTIC_TEST

Circulating tumor DNA (ctDNA) testing

Circulating tumor DNA (ctDNA) testing is a type of biopsy that analyzes fragments of DNA shed by cancer cells into the bloodstream. These fragments, known as ctDNA, can provide valuable information about the genetic makeup of a tumor without needing a traditional tissue biopsy.

Trial Locations (1)

27514

UNC Lineberger Comprehensive Cancer Center, Chapel Hill